[Updated] Australia Updates Listed Medicine Ingredients, Affecting Health Supplements
Sep 30, 2024
Sadie Shen
Australia updates permissible ingredients in listed medicines, including 1 new ingredient and 16 ingredients with revised requirements.
Editor's Note: This article tracks the updates on Therapeutic Goods (Permissible Ingredients) Determination in 2024.
In Australia, vitamin and herbal supplements are regulated as complementary medicines by the TGA. Most complementary medicines are included in the Australian Register of Therapeutic Goods (ARTG) as listed medicines. Those medicines may only contain ingredients from an approved list of ingredients whose quality, safety and suitability for use in such medicines have been evaluated. The approved list of ingredients can be found in the Therapeutic Goods (Permissible Ingredients) Determination.
Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2024
On September 27, 2024, Therapeutic Goods Administration (TGA) of Australia published a notice to announce the issuance of Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2024, which replaces the previous instrument. Major changes involve the addition of 1 new ingredient and the revision of requirements for 16 ingredients. The new determination takes effect from September 27, 2024.
Major changes
A complete list of the 17 involved ingredients is shown in the table below:
Substance name | Status |
Akkermansia muciniphila | Addition |
camphor oil brown | Change |
camphor oil white | Change |
creosote | Change |
EPA-rich Nannochloropsis oculata oil | Change |
glucosamine sulfate potassium chloride | Change |
hyoscyamus leaf dry | Change |
lime oil | Change |
Ocimum kilimandscharicum | Change |
orange oil bitter | Change |
Pimpinella anisum | Change |
potassium iodide | Change |
racemic camphor | Change |
selenomethionine | Change |
Strychnos ignatii | Change |
Strychnos nux-vomica | Change |
Terminalia ferdinandiana | Change |
Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2024
On June 14, 2024, Therapeutic Goods Administration (TGA) of Australia published a notice to announce the issuance of Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2024, replacing the previous instrument. Major changes involve the addition of 5 new ingredients and the revision of requirements for 4 ingredients. The new determination took effect on June 14, 2024.
A complete list of the 9 involved ingredients is shown in the table below:
Substance name | Status |
Bacillus subtilis | Addition |
behentrimonium metilsulfate | Addition |
D-glucose, polymer with xylitol | Addition |
1,8,12-bisabolatriene | Addition |
polyglyceryl-2 isostearate | Addition |
beeswax alcohols | Change |
Euglena gracilis whole cell dry | Change |
Litchi chinensis | Change |
nonivamide | Change |
Therapeutic Goods (Permissible Ingredients) Determination (No.1) 2024
On March 1, 2024, Therapeutic Goods Administration (TGA) of Australia published a notice to announce the issuance of Therapeutic Goods (Permissible Ingredients) Determination (No. 1) 2024, replacing the previous instrument. Major changes involve the addition of 3 new ingredients and the revision of requirements for 37 ingredients. The new determination took effect on March 1, 2024.
A complete list of the 40 involved ingredients is shown in the table below:
Substance name | Status | Major change |
ceramide 6 II | Addition | The specific requirements for this ingredient are as below: (a) Only be used in topical medicines for dermal application; and (b) Not be included in medicines intended for use on broken skin or in the eye. |
sodium lauroyl lactylate | Addition | The specific requirements for this ingredient are as below: (a) Only be used in topical medicines for dermal application; and (b) Not be included in medicines intended for use on broken skin or in the eye. |
theanine | Addition | The specific requirements for this ingredient are as below: Theanine must only be used in a medicine where Trans Chem Pty Ltd (Client ID 21878), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 1 March 2026. The route of administration for medicines that contain theanine must be limited to oral. The maximum recommended daily dose of the medicine must not provide more than 450 mg of theanine. The following warning statements (or words to the same effect) are required on the medicine label:
- (PREGNT) "Not recommended for use by pregnant and lactating women"; - (ADULT) "Adults only". |
neohesperidin-dihydrochalcone | Change | The Determination makes minor formatting changes and some other amendments to the specific; requirements for the ingredient, to permit oral use in listed and assessed listed medicines |
Chelidonium majus | Change | The Determination makes minor amendments to these ingredients to reflect the transition periods expiration for requirements relating to those ingredients |
Larrea tridentata | Change |
valerian Dry | Change |
valerian Powder | Change |
Valeriana officinalis | Change |
3'-sialyllactose sodium | Change | The Determination removes requirements for these ingredients to reflect the expiry of exclusive use periods for the relevant sponsors. |
6'-sialyllactose sodium | Change |
dihydrocapsiate | Change |
hydrolysed chicken cartilage extract | Change |
lacto-N-neotetraose | Change |
lacto-N-tetraose | Change |
hemp seed oil | Change | The Determination makes amendments to the specific requirements for this ingredient to align with the requirements in the Poisons Standard. |
Curcuma aromatica | Change | The Determination makes revisions to add a liver injury warning statement and the maximum recommended daily doses for children based on age |
Curcuma longa | Change |
Curcuma zanthorrhiza | Change |
Curcuma zedoaria | Change |
curcumin | Change |
Camellia sinensis | Change | The Determination makes revisions to add warning statements relating to liver injury, and to clarify the requirements for use as an excipient in flavour proprietary excipient formulations |
benzophenone | Change | The Determination makes revisions to remove the use as an excipient ingredient in flavour proprietary excipient formulations |
soy phosphatidylserine-enriched soy lecithin liquid | Change | The Determination makes revisions to amend the requirements regarding the maximum recommended daily dose, and remove the requirement that the concentration of soy phosphatidylserine must be no more than 15%. |
soy phosphatidylserine-enriched soy lecithin powder | Change |
Terminalia ferdinandiana | Change | The Determination makes revisions to clarify the requirements for the permitted plant part and preparation type when being used as an active ingredient |
ethyl methacrylate | Change | The Determination updates the requirements for these ingredients to align with requirements in the Poisons Standard, and makes minor formatting changes and correction of minor typographical errors. |
furfural | Change |
C10-12 alkane/cycloalkane | Change |
hydrogenated C6-14 olefin polymers | Change |
turpentine oil | Change |
lipase | Change |
cetylpyridinium chloride | Change |
artemisia oil | Change |
zinc para-phenolsulfonate | Change |
zinc stearate | Change |
zinc valerate | Change |
zinc lactate | Change |
zinc lactate dihydrate | Change |
Phleum pratense | Change |

We provide full-scale global food market entry services (including product registration, ingredient review, regulatory consultation, customized training, market research, branding strategy). Please contact us to discuss how we can help you by
food@chemlinked.com
Copyright: unless otherwise stated all contents of this website are ©2025 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact
cleditor@chemlinked.com